Research Paper Volume 15, Issue 21 pp 12651—12673

Discovery and identification of the prognostic significance and potential mechanism of FMO2 in breast cancer

class="figure-viewer-img"

Figure 4. High FMO2 expression was sensitive to immunotherapy in OS. (A) Anti-PD-1 immunotherapy. (B) Anti-PD-L1 immunotherapy. (C) Anti-CTLA-4 immunotherapy. (D) Pembrolizumab immunotherapy. (E) Nivolumab immunotherapy. (F) Atezolizumab immunotherapy. (G) Ipilimumab immunotherapy.